-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s Cevaretigene Ritoparvovec
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's Cevaretigene Ritoparvovec report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s AAV-GAD
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's AAV-GAD report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s AAV-AQP1
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's AAV-AQP1 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – MeiraGTx Holdings Plc
MeiraGTx Holdings Plc (MeiraGTx) is a gene therapy company that develops treatments for ocular, salivary gland and central nervous system diseases. It is investigating AAV-RPGR program against X-linked retinitis pigmentosa (XLRP); AAV-RPE65 gene therapy to treat RPE65 (retinal pigment epithelium-specific 65 kDa) gene deficiency; AAV-CNGB3 drug for achromatopsia (ACHM); and A006 program targeting wet AMD (age-related macular degeneration). The company is also evaluating AAV-GAD medicine to treat Parkinson’s disease; AAV-UPF1 against amyotrophic lateral sclerosis (ALS); AAV-AQP1 for radiation-induced xerostomia (RIX);...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Nemtabrutinib
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Nemtabrutinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: PTC Therapeutics Inc’s Sepiapterin
Empower your strategies with our Net Present Value Model: PTC Therapeutics Inc's Sepiapterin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1 in Xerostomia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAV-AQP1 in Xerostomia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAV-AQP1 in Xerostomia Drug Details: AAV-AQP1 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s Botaretigene Sparoparvovec
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's Botaretigene Sparoparvovec report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecnoglutide in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ecnoglutide in Type 2 Diabetes Drug Details: XW-003 is under development...
-
Company Insights
Innovation and Patenting activity of MeiraGTx Holdings Plc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of MeiraGTx Holdings Plc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...